ABC | Volume 113, Nº4, Outubro 2019

Atualização Atualização da Diretriz de Prevenção Cardiovascular da Sociedade Brasileira de Cardiologia – 2019 Arq Bras Cardiol. 2019; 113(4):787-891 1. Nascimento BR, Brant LCC, Oliveira GMM, Malachias MVB, Reis GMA, Teixeira RA, et al. Cardiovascular Disease Epidemiology in Portuguese- Speaking Countries: data from the Global Burden of Disease, 1990 to 2016. Arq Bras Cardiol. 2018;110(6):500-11. 2. Simão AF, Precoma DB, Andrade JP, Correa FH, Saraiva JF, Oliveira GM, et al. Brazilian Guidelines for cardiovascular prevention. Arq Bras Cardiol. 2013;101(6 Suppl 2):1-63. 3. World Health Organization. (WHO). 65th World Health Assembly document A65/54: Second report of Committee A, 2012. [Internet] [Cited in 2019May 20]. Available from: http://apps.who.int/gb/ebwha/pdf_files/ WHA65/ A65_54-en.pdf. 4. Brant LCC, Nascimento BR, Passos VMA, Duncan BB, Bensenõr IJM,Malta DC, et al. Variations and particularities in cardiovascular diseasemortality in Brazil and Brazilian states in 1990 and 2015: estimates from the Global Burden of Disease. Rev Bras Epidemiol. 2017;20(Suppl 1):116-28. 5. Brasil. Ministério da Saúde. Secretaria de Vigilância a Saúde. Plano de ações estratégicas para o enfrentamento das doenças crônicas não transmissíveis no Brasil, 2011-2022. Brasilia;2012. 6. D'Agostino RB Sr, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM, et al. General cardiovascular risk profile for use in primary care: the FraminghamHeart Study. Circulation. 2008;117(6):743-53. 7. Faludi AA, IzarMCO, Saraiva JFK, Chacra APM, BiancoHT, Afiune ANeto, etal.SociedadeBrasileiradeCardiologia.AtualizaçãodaDiretrizBrasileira de Dislipidemias e Prevenção da Aterosclerose – 2017. Arq Bras Cardiol. 2017;109(2 Suppl 1):1-76. 8. Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol. Circulation. 2018Nov 10:CIR0000000000000625. [Epub ahead of print] 9. Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice. The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts). Eur Heart J. 2016;37(29):2315-81. 10. Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease. Circulation. 2019Mar 17:0000000000000677. [Epub ahead of print] 11. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364(9438):937-52. 12. Ference BA, GinsbergHN, Graham I, Ray KK, Packard CJ, Bruckert E, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017;38(32):2459-72. 13. Cholesterol Treatment Trialists C, Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010; 376(9753):1670-81. 14. Navarese EP, Robinson JG, Kowalewski M, Kolodziejczak M, Andreotti F, Bliden K, et al. Association Between Baseline LDL-C Level and Total and Cardiovascular Mortality After LDL-C Lowering: A Systematic Review and Meta-analysis. JAMA. 2018;319(15):1566-79. 15. Scartezini M, Ferreira CE, Izar MC, Bertoluci M, Vencio S, Campana GA, et al. Positioning about the flexibility of fasting for lipid profiling. Arq Bras Cardiol. 2017;108(3):195-7. 16. Nordestgaard BG, Chapman MJ, Ray K, Boren J, Andreotti F, Watts GF, et al. European Atherosclerosis Society Consensus Panel. Lipoprotein(a) as cardiovascular risk factor: current status. Eur Heart J. 2010;31(23):2844-53. 17. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al. Cholesterol Treatment Trialists’ (CTT) Collaborators. Efficacy and safety of cholesterol lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366(9493):1267-78. Erratum in: Lancet. 2005;366(9494):1358; Lancet. 2008;371(9630):2084. 18. Nordestgaard BG, ChapmanMJ, Humphries SE, Ginsberg HN, Masana L, Descamps OS, et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J. 2013;34(45):3478-90a. 19. Santos RD, Gagliardi AC, Xavier HT, Casella Filho A, Araújo DB, Cesena FY, et al; Sociedade Brasileira de Cardiologia. I Diretriz Brasileira de Hipercolesterolemia Familiar (HF). Arq Bras Cardiol. 2012;99(2 Suppl 2):1-28. 20. GrundySM,StoneNJ,BaileyAL,BeamC,BirtcherKK,BlumenthalRS,etal. 2018AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/ PCNA. Guideline on the Management of Blood Cholesterol: Executive Summary, J AmColl Cardiol. 2018, Nov 3.pii:S0735-1097(18):39033-8. 21. Thompson WG, Gau GT. Hypertriglyceridemia and its pharmacologic treatment among US adults--invited commentary. Arch Intern Med. 2009;169(6):578-9. 22. Wittrup HH, Tybjaerg-Hansen A, Nordestgaard BG. Lipoprotein lipase mutations, plasma lipids and lipoproteins, and risk of ischemic heart disease. A meta-analysis. Circulation. 1999;99(22):2901-7. 23. Sprecher DL, Harris BV, Stein EA, Bellet PS, Keilson LM, Simbartl LA. Highertriglycerides, lowerhigh-density lipoproteincholesterol,andhigher systolic blood pressure in lipoprotein lipase-deficient heterozygotes. A preliminary report. Circulation. 1996;94(12):3239-45. 24. Hypertriglyceridaemia and vascular risk. Report of ameeting of physicians and scientists, University College London Medical School. Lancet. 1993;342(8874):781-7. 25. Miller BD, Alderman EL, Haskell WL, Fair JM, Krauss RM. Predominance of dense low-density lipoprotein particles predicts angiographic benefit of therapy in the Stanford Coronary Risk Intervention Project. Circulation. 1996;94(9):2146-53. 26. Brunzell JD. Clinical practice. Hypertriglyceridemia. N Engl J Med. 2007;357(10):1009-17. 27. DeFronzo RA, Ferrannini E. Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atheroscleroticcardiovasculardisease.DiabetesCare.1991;14(3):173-94. 28. McLaughlin T, Abbasi F, Cheal K, Chu J, Lamendola C, Reaven G. Use of metabolic markers to identify overweight individuals who are insulin resistant. Ann Intern Med. 2003;139(10):802-9. 29. Simpson HC, Mann JI, Meade TW, Chakrabarti R, Stirling Y, Woolf L. Hypertriglyceridaemiaandhypercoagulability.Lancet.1983;1(8328):786- 90. 30. Humphries SE, Lane A, Green FR, Cooper J, Miller GJ. Factor VII coagulant activity and antigen levels in healthy men are determined by interaction between factor VII genotype and plasma triglyceride concentration. Arterioscler Thromb. 1994;14(2):193-8. 31. Rosenson RS, Shott S, Lu L, Tangney CC. Hypertriglyceridemia and other factors associated with plasma viscosity. Am J Med. 2001;110(6):488-92. 32. Santos RD, Gagliardi AC, Xavier HT, Magnoni CD, Cassani R, Lottenberg AM; Sociedade Brasileira de Cardiologia. First guidelines on fat Referências 873